Veracyte, Inc.
VCYT
$30.43
-$0.53-1.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.46% | 23.95% | 21.59% | 20.66% | 21.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.46% | 23.95% | 21.59% | 20.66% | 21.76% |
| Cost of Revenue | 20.98% | 17.23% | 13.57% | 14.75% | 13.48% |
| Gross Profit | 24.79% | 27.71% | 26.29% | 24.22% | 26.69% |
| SG&A Expenses | 5.33% | 8.27% | 2.56% | 4.16% | 8.21% |
| Depreciation & Amortization | -27.81% | -25.71% | -17.99% | -10.86% | -3.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.42% | 12.76% | 8.66% | 10.22% | 12.31% |
| Operating Income | 254.04% | 182.63% | 122.14% | 82.19% | 56.36% |
| Income Before Tax | 133.60% | 83.52% | -91.02% | -134.34% | -110.32% |
| Income Tax Expenses | 172.74% | 193.32% | -299.47% | -1,755.88% | -1,760.15% |
| Earnings from Continuing Operations | 132.44% | 81.45% | -85.96% | -125.83% | -103.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.44% | 81.45% | -85.96% | -125.83% | -103.51% |
| EBIT | 254.04% | 182.63% | 122.14% | 82.19% | 56.36% |
| EBITDA | 442.98% | 412.66% | 629.21% | 317.36% | 162.96% |
| EPS Basic | 130.60% | 79.63% | -84.47% | -122.15% | -99.73% |
| Normalized Basic EPS | 501.73% | 320.36% | 168.89% | 110.52% | 76.26% |
| EPS Diluted | 128.80% | 78.16% | -84.61% | -123.89% | -101.15% |
| Normalized Diluted EPS | 495.47% | 317.80% | 168.68% | 110.52% | 76.26% |
| Average Basic Shares Outstanding | 5.28% | 4.19% | 3.15% | 2.09% | 1.53% |
| Average Diluted Shares Outstanding | 6.79% | 4.91% | 3.37% | 2.09% | 1.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
